Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program

Nicholas E. Johnson, MD, MSCI, Russell J. Butterfield, MD, PhD, Katie Mayne, BS, et al.

Cite as: Neurology® 2021;96:e1045-e1053. doi:10.1212/WNL.0000000000011425

Study Question
Is the prevalence of CTG expansions in the DMPK gene in patients with myotonic dystrophy type 1 higher than previously reported?

What Is Known and What This Paper Adds
Myotonic dystrophy type 1 is caused by CTG expansion ≥50 repeats in the DMPK gene, and has an estimated prevalence of 0.5–2 people per 10,000 individuals in the general population. However, this is likely an underestimate due to a cross-section of the population who may be pauci-symptomatic or pre-symptomatic. This investigation’s results suggest that the actual prevalence is up to 5 times higher than previously estimated.

Methods
For this cross-sectional study, the investigators analyzed genetic data from 50,382 babies consecutively born at hospitals throughout the state of New York between December 2013 and April 2014 who underwent dried blood spot collection through the state’s Newborn Screening Program. The investigators conducted melt curve analysis of the blood spots, and 4 blinded reviewers independently reviewed melt curve morphologies to identify samples with possible CTG expansions in the DMPK gene. To determine whether flagged samples actually contained CTG expansions, the investigators conducted further testing with a repeat-primed PCR procedure involving capillary electrophoresis, and they regarded the presence of ≥50 CTG repeats as a positive result. The primary outcome was the overall prevalence of CTG expansions in the DMPK gene.

Results and Study Limitations
Overall, the investigators detected 24 samples with ≥50 CTG repeats in the DMPK gene. This represents a prevalence of 4.76 cases per 10,000 births (95% CI, 2.86–6.67) or 1 case for every 2,100 births. The investigators also detected 96 samples with expansions from 35–49 CTG repeats, with the resulting prevalence for such shorter repeat expansions being 19.1 cases per 10,000 births or 1 case for every 525 births. These premutation carriers represent the risk pool for further expansion in subsequent generations. The present study’s limitations include a lack of data concerning clinical features and a focus on a single US state, which may limit generalizability.

Study Funding and Competing Interests
This study was funded by the Myotonic Dystrophy Foundation. Some authors report receiving consulting fees, committee appointments, and funding from healthcare companies; receiving funding from US government agencies; and receiving royalties for the use of clinical indices. Go to Neurology.org/N for full disclosures.
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program
Nicholas E. Johnson, Russell J. Butterfield, Katie Mayne, et al.

Neurology 2021;96:e1045-e1053 Published Online before print January 20, 2021
DOI 10.1212/WNL.0000000000011425

This information is current as of January 20, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/96/7/e1045.full

References
This article cites 20 articles, 5 of which you can access for free at:
http://n.neurology.org/content/96/7/e1045.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Muscle disease
http://n.neurology.org/cgi/collection/muscle_disease
Prevalence studies
http://n.neurology.org/cgi/collection/prevalence_studies

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise